Bioventix (BVXP) Competitors

Bioventix logo
GBX 1,896.55 -53.45 (-2.74%)
As of 11/20/2026 11:53 AM Eastern

BVXP vs. APH, BXP, ANCR, AGY, and VLG

Should you buy Bioventix stock or one of its competitors? Bioventix's main competitors and comparable companies include Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Allergy Therapeutics (AGY), and Venture Life Group (VLG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bioventix compare to Alliance Pharma?

Alliance Pharma (LON:APH) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Bioventix has lower revenue, but higher earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A
Bioventix£12.97M7.64£8.12M£143.6213.21

In the previous week, Alliance Pharma's average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
Alliance Pharma Neutral
Bioventix Neutral

66.3% of Alliance Pharma shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 12.0% of Alliance Pharma shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 7.9%. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Bioventix pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.541, indicating that its share price is 46% less volatile than the broader market.

Bioventix has a net margin of 58.70% compared to Alliance Pharma's net margin of -6.00%. Bioventix's return on equity of 67.81% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Alliance Pharma-6.00% -5.04% 5.98%
Bioventix 58.70%67.81%54.07%

Summary

Bioventix beats Alliance Pharma on 8 of the 13 factors compared between the two stocks.

How does Bioventix compare to Beximco Pharmaceuticals?

Bioventix (LON:BVXP) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bioventix has a net margin of 58.70% compared to Beximco Pharmaceuticals' net margin of 16.93%. Bioventix's return on equity of 67.81% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix58.70% 67.81% 54.07%
Beximco Pharmaceuticals 16.93%15.99%6.97%

Beximco Pharmaceuticals has higher revenue and earnings than Bioventix. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.97M7.64£8.12M£143.6213.21
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03

Bioventix has a beta of 0.541, indicating that its share price is 46% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, indicating that its share price is 75% less volatile than the broader market.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Beximco Pharmaceuticals Neutral

Summary

Bioventix beats Beximco Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Bioventix compare to Animalcare Group?

Animalcare Group (LON:ANCR) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

14.3% of Animalcare Group shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 30.1% of Animalcare Group shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bioventix has a net margin of 58.70% compared to Animalcare Group's net margin of 5.70%. Bioventix's return on equity of 67.81% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Animalcare Group5.70% 4.46% 2.97%
Bioventix 58.70%67.81%54.07%

Animalcare Group has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.541, indicating that its stock price is 46% less volatile than the broader market.

Animalcare Group pays an annual dividend of GBX 5.20 per share and has a dividend yield of 1.6%. Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 7.9%. Animalcare Group pays out 71.2% of its earnings in the form of a dividend. Bioventix pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, Animalcare Group's average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
Animalcare Group Neutral
Bioventix Neutral

Animalcare Group has higher revenue and earnings than Bioventix. Bioventix is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Animalcare Group£89.11M2.60£36.55M£7.3045.89
Bioventix£12.97M7.64£8.12M£143.6213.21

Summary

Bioventix beats Animalcare Group on 7 of the 13 factors compared between the two stocks.

How does Bioventix compare to Allergy Therapeutics?

Allergy Therapeutics (LON:AGY) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bioventix has a net margin of 58.70% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Bioventix's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-86.04% 1,684.19% -34.76%
Bioventix 58.70%67.81%54.07%

Allergy Therapeutics has a beta of 0.835, meaning that its share price is 17% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.541, meaning that its share price is 46% less volatile than the broader market.

In the previous week, Allergy Therapeutics had 4 more articles in the media than Bioventix. MarketBeat recorded 4 mentions for Allergy Therapeutics and 0 mentions for Bioventix. Allergy Therapeutics' average media sentiment score of 0.02 beat Bioventix's score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Allergy Therapeutics Neutral
Bioventix Neutral

Bioventix has lower revenue, but higher earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£59.87M1.19-£52.59M-£0.97N/A
Bioventix£12.97M7.64£8.12M£143.6213.21

Summary

Bioventix beats Allergy Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Bioventix compare to Venture Life Group?

Bioventix (LON:BVXP) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Bioventix has a beta of 0.541, indicating that its share price is 46% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.234, indicating that its share price is 77% less volatile than the broader market.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Venture Life Group'saverage media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Venture Life Group Neutral

Bioventix has higher earnings, but lower revenue than Venture Life Group. Bioventix is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.97M7.64£8.12M£143.6213.21
Venture Life Group£35.17M2.25£747.21K£4.3715.22

20.6% of Bioventix shares are held by institutional investors. Comparatively, 20.7% of Venture Life Group shares are held by institutional investors. 6.2% of Bioventix shares are held by company insiders. Comparatively, 7.7% of Venture Life Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bioventix has a net margin of 58.70% compared to Venture Life Group's net margin of 17.42%. Bioventix's return on equity of 67.81% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix58.70% 67.81% 54.07%
Venture Life Group 17.42%7.82%1.56%

Summary

Bioventix beats Venture Life Group on 7 of the 11 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BVXP vs. The Competition

MetricBioventixPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£99.10M£13.62B£7.78B£2.67B
Dividend Yield7.69%2.58%2.47%5.11%
P/E Ratio13.2127.5233.2222.78
Price / Sales7.646.788.104.91
Price / Cash30.8915.6321.0120.23
Price / Book8.255.164.262.40
Net Income£8.12M£2.86B£3.50B£5.88B
1 Month Performance-2.74%-9.80%-10.48%-4.75%
1 Year Performance-7.80%-8.93%-4.61%5.15%

Bioventix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BVXP
Bioventix
N/AGBX 1,896.55
-2.7%
N/A-9.3%£99.10M£12.97M13.2112
APH
Alliance Pharma
N/AGBX 64.70
flat
N/AN/A£350.32M£183.50MN/A91,000
BXP
Beximco Pharmaceuticals
N/AGBX 61.85
+3.1%
N/A+39.3%£275.90M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 335
flat
N/AN/A£231.30M£89.11M45.89220
AGY
Allergy Therapeutics
N/AGBX 1.49
flat
N/A-87.2%£94.36M£57.29MN/A612

Related Companies and Tools


This page (LON:BVXP) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners